These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25908995)

  • 1. Response to Pneumococcal Polysaccharide Vaccination in Newly Diagnosed HIV-Positive Individuals.
    Leggat DJ; Iyer AS; Ohtola JA; Kommoori S; Duggan JM; Georgescu CA; Khuder SA; Khaskhely NM; Westerink MJ
    J AIDS Clin Res; 2015 Feb; 6(2):. PubMed ID: 25908995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to Pneumococcal Polysaccharide Vaccination in HIV-Positive Individuals on Long Term Highly Active Antiretroviral Therapy.
    Iyer AS; Leggat DJ; Ohtola JA; Duggan JM; Georgescu CA; Al Rizaiza AA; Khuder SA; Khaskhely NM; Westerink J
    J AIDS Clin Res; 2015 Feb; 6(2):. PubMed ID: 25908996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
    Farmaki PF; Chini MC; Mangafas NM; Tzanoudaki MT; Piperi CP; Lazanas MZ; Spoulou VS
    J Infect Dis; 2018 Jun; 218(1):26-34. PubMed ID: 29722823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
    Gaultier GN; McCready W; Ulanova M
    BMC Immunol; 2019 Nov; 20(1):41. PubMed ID: 31718534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults.
    Ohtola JA; Saul-McBeth JL; Iyer AS; Leggat DJ; Khuder SA; Khaskhely NM; Westerink MJ
    J AIDS Clin Res; 2016 Mar; 7(3):. PubMed ID: 27158552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
    Lee KY; Tsai MS; Kuo KC; Tsai JC; Sun HY; Cheng AC; Chang SY; Lee CH; Hung CC
    Hum Vaccin Immunother; 2014; 10(12):3700-10. PubMed ID: 25483681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.
    Zou X; He J; Zheng J; Liang M; Gao J; Huang J; Jiang Y; Jiang Y; Chen X
    Vaccine; 2022 Jan; 40(1):37-42. PubMed ID: 34857419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.
    Lu CL; Chang SY; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Hung CC
    Vaccine; 2014 Feb; 32(9):1031-5. PubMed ID: 24440112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
    Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
    HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.
    Ho YL; Brandão AP; de Cunto Brandileone MC; Lopes MH
    Vaccine; 2013 Aug; 31(37):4047-53. PubMed ID: 23684823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of vaccination with seven-valent pneumococcal conjugate vaccine on virologic and immunologic outcomes among HIV-infected adult patients in the era of highly active antiretroviral therapy.
    Lu CL; Chang SY; Sun HY; Liu WC; Tseng YT; Hsieh CY; Wu CH; Hung CC; Chang SC
    J Formos Med Assoc; 2012 Aug; 111(8):445-51. PubMed ID: 22939663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
    Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reactogenicity, safety, immunogenicity and prophylactic effectiveness of polysaccharide pneumococcus vaccine during immunization of HIV-infected patients].
    Fel'dblium IV; Nikolenko VV; Vorob'eva NN; Ivanova ÉS; Shmagel' NG; Khafizov KM; Iurganova GA; Zverev SIa
    Zh Mikrobiol Epidemiol Immunobiol; 2013; (3):52-60. PubMed ID: 24000594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response.
    Chen Z; Cox KS; Tang A; Roman J; Fink M; Kaufhold RM; Guan L; Xie A; Boddicker MA; Mcguinness D; Xiao X; Li H; Skinner JM; Verch T; Retzlaff M; Vora KA
    BMC Infect Dis; 2018 Dec; 18(1):613. PubMed ID: 30509199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The controversial impact of B cells subsets on immune response to pneumococcal vaccine in HIV-1 patients.
    Tsachouridou O; Skoura L; Zebekakis P; Margariti A; Georgiou A; Daniilidis M; Malisiovas N; Metallidis S
    Int J Infect Dis; 2015 Sep; 38():24-31. PubMed ID: 26192868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.
    Lombardi F; Belmonti S; Fabbiani M; Morandi M; Rossetti B; Tordini G; Cauda R; De Luca A; Di Giambenedetto S; Montagnani F
    PLoS One; 2016; 11(6):e0156523. PubMed ID: 27258647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 23-valent pneumococcal polysaccharide vaccine elicits hierarchical antibody and cellular responses in healthy and tuberculosis-cured elderly, and HIV-1-infected subjects.
    Huang H; Qian X; Pan R; Shen L; Liang S; Wang F; Zhang P; Shen H; Chen ZW
    Clin Immunol; 2018 Aug; 193():1-9. PubMed ID: 29753126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.